Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025

Page 13 of 14

2. GH Research PLC (NASDAQ:GHRS)

Number of Hedge Fund Holders In Q3 2024: 9

GH Research PLC (NASDAQ:GHRS) is a biopharma company that makes psychiatric and neurological therapies.

The stock has surged so far in 2025 due to its Phase 2b trial results for GH001 in TRD. It showed a 15.5-point placebo-adjusted reduction in MADRS (Montgomery-Åsberg Depression Rating Scale) scores by Day 8 (p<0.0001). 57.5% of GH001 patients achieved remission vs. 0% in the placebo group.

Not only that, 77.8% of patients remained in remission at 6 months, with infrequent treatments required.

The company has also Resolved FDA concerns about respiratory toxicity in non-rodent studies. This cleared a hurdle for its Investigational New Drug (IND) application. It now plans to submit a full FDA response in mid-2025 to lift the IND clinical hold.

The consensus price target of $35.67 implies 98.06% upside.

GHRS stock is up 180.7% year-to-date.

Page 13 of 14